Literature DB >> 30426234

Persistent eosinophilia in rheumatoid arthritis: a prospective observational study.

Dantis Emmanuel1,2, Subhash Chandra Parija3,4, Ankit Jain1,5, Durga Prasanna Misra1,6, Rakhee Kar7, Vir Singh Negi8.   

Abstract

Eosinophilia is an uncommon manifestation in Rheumatoid arthritis (RA), and there is a paucity of data regarding the relationship of eosinophilia with disease-related factors. We prospectively evaluated the clinical and disease-specific characteristics of RA patients with eosinophilia. Consecutive patients with RA with an absolute eosinophil count ≥ 500/mm3 without an apparent cause for eosinophilia, were investigated for parasitic infestation. Patients with a definite parasitic infestation received targeted therapy, and the rest were treated with albendazole empirically. The RA disease-specific characteristics of the patients with persistent eosinophilia were compared with the patients without eosinophilia. Of the 160 patients with eosinophilia, 30 patients (19%) had allergic diseases, six patients had bronchiectasis, and one patient had hypereosinophilia of undetermined significance. Intestinal helminthiasis was found in 34 patients (21%). Eosinophilia was unexplained in 89 patients (56%) and it resolved after empirical albendazole therapy in about two-thirds (58 patients). Thirty-one patients had persistent eosinophilia. Nonsteroidal anti-inflammatory drug and disease-modifying antirheumatic drug modification did not show any effect on eosinophilia. The disease-related characteristics were similar between patients with persistent eosinophilia and those without eosinophilia. Eosinophilia is due to secondary causes in the majority of RA patients, and the most common cause in our setting is an intestinal helminthic infection. Persistent eosinophilia in our cohort of RA did not indicate a more severe disease phenotype.

Entities:  

Keywords:  Albendazole; Disease activity; Eosinophilia; Intestinal helminthiasis; Rheumatoid arthritis

Mesh:

Year:  2018        PMID: 30426234     DOI: 10.1007/s00296-018-4191-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  30 in total

Review 1.  Practical approach to the patient with hypereosinophilia.

Authors:  Florence Roufosse; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2010-06-09       Impact factor: 10.793

2.  Eosinophilia during psoriasis treatment with TNF antagonists.

Authors:  Bartosz Malisiewicz; Carla Murer; Jana Pachlopnik Schmid; Lars E French; Peter Schmid-Grendelmeier; Alexander A Navarini
Journal:  Dermatology       Date:  2012-02-02       Impact factor: 5.366

3.  Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis.

Authors:  Kathleen Morrisroe; Melinda Wong
Journal:  Rheumatology (Oxford)       Date:  2015-07-29       Impact factor: 7.580

4.  Prevalence of intestinal parasites in rural Southern Indians.

Authors:  G Kang; M S Mathew; D P Rajan; J D Daniel; M M Mathan; V I Mathan; J P Muliyil
Journal:  Trop Med Int Health       Date:  1998-01       Impact factor: 2.622

5.  Observations on the eosinophilia of certain patients with rheumatoid arthritis.

Authors:  R J Winchester; D Koffler; S D Litwin; H G Kunkel
Journal:  Arthritis Rheum       Date:  1971 Sep-Oct

Review 6.  Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction.

Authors:  Marie-Christophe Boissier; Luca Semerano; Salima Challal; Nathalie Saidenberg-Kermanac'h; Géraldine Falgarone
Journal:  J Autoimmun       Date:  2012-06-16       Impact factor: 7.094

7.  Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.

Authors:  J D Greenberg; G Reed; J M Kremer; E Tindall; A Kavanaugh; C Zheng; W Bishai; M C Hochberg
Journal:  Ann Rheum Dis       Date:  2009-04-08       Impact factor: 19.103

8.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

9.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

Review 10.  Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort.

Authors:  Dewi Guellec; Morgane Milin; Divi Cornec; Gabriel J Tobon; Thierry Marhadour; Sandrine Jousse-Joulin; Gilles Chiocchia; Olivier Vittecocq; Valérie Devauchelle-Pensec; Alain Saraux
Journal:  RMD Open       Date:  2015-07-15
View more
  2 in total

Review 1.  Emerging Role of Eosinophils in Resolution of Arthritis.

Authors:  Yi Qin; Hui-Zhi Jin; Yu-Jing Li; Zhu Chen
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

2.  Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients.

Authors:  Evelina Elmér; Per Nived; Åsa Pettersson; Lillemor Skattum; Thomas Hellmark; Meliha C Kapetanovic; Åsa C M Johansson
Journal:  J Immunol Res       Date:  2022-07-28       Impact factor: 4.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.